SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
LQR House Inc. consummated an additional closing on June 1, 2026, acquiring an additional 3,000 shares (30%) of Fusion Five Continents Securities Limited for $39,000,000 in Tether (USDT), bringing total ownership to 54%. This is a material acquisition activity disclosed under Item 1.01 (Entry into a Material Definitive Agreement), representing a substantial equity investment and change of control interest in the target company.
View raw filing on EDGAR →USA Rare Earth entered into a material definitive agreement on June 1, 2026, for a 20-year lease of an 800,000 square foot specialty rare earth magnet manufacturing facility in South Carolina, with an expected investment of approximately $800 million and creation of 325 new jobs. This represents a material commitment to a major capital project and operational expansion that significantly affects the registrant's financial position and strategic direction.
View raw filing on EDGAR →Virtuix amended three warrants with Streeterville Capital to reduce the exercise price from $6.00 to $4.00 per share and extend the Reduced Exercise Price Period through July 27, 2026, substantially increasing the likelihood and incentive for warrant exercise and effectively diluting existing shareholders.
View raw filing on EDGAR →The filing discloses a previously announced business combination between Iron Horse Acquisition II Corp. (IRHO) and Electra Vehicles, Inc., with an updated investor presentation released on June 2, 2026. The disclosure explicitly references the "proposed Business Combination" and indicates that IRHO and Electra intend to jointly file a Form S-4 registration statement with a proxy statement/prospectus for shareholder approval. This constitutes material M&A activity requiring disclosure under Item 1.01 or related provisions, even though disclosed under Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →The filing discloses an unregistered sale of 440,241.448 shares of common stock for $4,376,000 pursuant to subscription agreements, exempt under Section 4(a)(2) and Regulation D. This is a classic private placement dilutive issuance. The material aggregate offering price and substantial share count make this material to investors assessing ownership dilution and capital structure.
View raw filing on EDGAR →OSR Holdings entered into an Asset Purchase Agreement on May 27, 2026 to acquire intellectual property assets (the VXM01 patent family, know-how, regulatory filings, and clinical data) from its subsidiary Vaximm for $30 million. This constitutes a material acquisition of assets with a defined purchase price and closing conditions, fitting the ma_activity classification. The transaction is material to investors as it restructures ownership of valuable IP assets and triggers future milestone payment obligations under the related License Agreement.
View raw filing on EDGAR →INmune Bio announced exploratory chi-separation MRI imaging results from the Phase 2 MINDFuL clinical trial of XPro1595 in early Alzheimer's disease patients. While this is a clinical trial result disclosure, it does not fit the standard "earnings_release" category (which typically covers quarterly/annual financial results) and appears to be a material clinical development update that would affect investor assessment of the company's pipeline progress. Classified as other_material given the clinical-stage nature of the disclosure and its significance to a biotech company's valuation.
View raw filing on EDGAR →ISQ Open Infrastructure issued approximately 321,000 unregistered shares across multiple share classes for aggregate net consideration of $12,965,396 as of May 1, 2026, under Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →The filing discloses a material acquisition/business combination transaction in which IQM Finland Oy will become a publicly traded company through a merger with RAAQ. The Item 8.01 disclosure announces an additional USD 12 million PIPE commitment from Ilmarinen, bringing total PIPE commitments to over USD 146 million in connection with the Transaction. This is a continuation of the previously announced business combination agreement dated February 22, 2026, and represents a material change of control event that would significantly affect investor assessment of the registrant.
View raw filing on EDGAR →The filing discloses entry into a material definitive agreement—an Intercreditor Agreement dated May 27, 2026—that establishes the priority and subordination of multiple lenders' claims against Everli and related parties in connection with a proposed business combination between Melar and Everli. While the intercreditor agreement itself is a financing arrangement, it is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and is material to the proposed merger transaction between Melar and Everli, which is the underlying M&A activity referenced throughout the filing. The agreement directly supports and facilitates the business combination by clarifying lender priorities and consent, making it integral to the M&A activity.
View raw filing on EDGAR →The disclosure announces the appointment of Dr. Supriyo Bandyopadhyay as Lead Technical Advisor of AI Nanomagnetic Technology, a senior technical leadership role guiding development of the Company's core nanomagnetic AI chip technology for space and defense markets. This executive appointment is material to investors assessing the Company's technical capability and strategic direction in a key technology area.
View raw filing on EDGAR →The section header indicates Item 5.02 disclosure covering departures, elections, appointments, and/or compensatory arrangements, but the actual prose content was not provided. Without the specific details of what occurred (e.g., whether an executive departed, was appointed, received compensation, or some combination), I cannot reliably classify this into a more specific event type. I am marking it as material because Item 5.02 disclosures typically involve material executive changes, but the confidence is low due to missing content.
View raw filing on EDGAR →SunPower announced its intention to offer common stock in lieu of cash interest payments on convertible senior notes due 2029. This represents a dilutive equity issuance triggered by financial stress—the company is substituting equity for cash debt service, a classic sign of liquidity constraints. The conversion of debt obligations into equity dilutes existing shareholders and signals potential financial distress.
View raw filing on EDGAR →The filing discloses the appointment of Daniel Clifford Rogers as a member of the Board and chair of the Audit Committee on June 2, 2026, replacing Dr. Risa Stack. While Dr. Stack's resignation is mentioned, the principal disclosed action centers on Mr. Rogers taking a role—specifically a board seat and audit committee chair position—making this an exec_appointment event. The appointment is material as it involves a change in board composition and audit committee leadership at an acquisition company.
View raw filing on EDGAR →NKGen Biotech entered into a Third Amendment to its Secured Convertible Loan Agreement on May 27, 2026, receiving $2.2 million in net proceeds through an unregistered sale of equity securities including a convertible promissory note (Additional Note #3) convertible at $0.08 per share, warrants exercisable at the same price, and 12,953,947 consideration shares to be delivered over 30 months. The transaction creates substantial dilution to existing shareholders through conversion, warrant exercise, and direct share issuance, typical of cash-strapped biotech financing.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) by the Federal Home Loan Bank of San Francisco. Schedule A details a $10 million fixed-rate bond (CUSIP 3130BAXB8) with a 4.25% coupon, maturing 6/04/2031, traded on 5/29/2026. While Item 2.03 is the designated item for creation of direct financial obligations, the filing itself notes that "consolidated obligations issuance is material to the Bank" and the Bank has not made materiality judgments on particular issuances. This represents a routine debt issuance by a Federal Home Loan Bank, which is material to the institution's capital structure but is a standard operational activity for such entities. The event does not fit neatly into more specific categories (not M&A, not a covenant breach, not a restatement), making "other_material" the most appropriate classification.
View raw filing on EDGAR →Jan Vleugals, Chief Operating Officer International, provided notice of retirement effective September 30, 2026, after more than a decade of service. Bob Calver will assume the role effective October 1, 2026.
View raw filing on EDGAR →This Item 2.03 disclosure describes the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) by the Federal Home Loan Bank of Des Moines. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the disclosure is primarily informational and regulatory in nature, explaining the mechanics and joint-and-several structure of FHLB debt rather than announcing a specific new obligation event. The absence of a Schedule A with specific issuance details and the boilerplate nature of the disclosure suggest this is a routine periodic reporting of the Bank's debt issuance framework rather than a discrete material event triggering Item 2.03.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (debt securities) totaling approximately $170 million across five tranches with trade dates of 05/27/2026 and 05/29/2026. While Item 2.03 is technically titled "Creation of a Direct Financial Obligation," the filing itself states "although consolidated obligations issuance is material to the FHLBank, we have not made a judgment as to the materiality of any particular consolidated obligation or obligations." The disclosure is routine debt issuance reporting for a Federal Home Loan Bank, not a covenant breach, going-concern issue, or other acute financial stress signal. However, the creation of direct financial obligations of this magnitude is material to investors assessing the registrant's capital structure and leverage, warranting classification as a material event that does not fit the more specific taxonomy categories.
View raw filing on EDGAR →GameStop Corp. issued a press release on June 2, 2026 announcing financial results for the first quarter ended May 2, 2026, disclosing quarterly financial performance.
View raw filing on EDGAR →GameStop's Board approved a new $2.0 billion share repurchase authorization, replacing the previous authorization, signaling the company's capital allocation strategy.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of Consolidated Obligations (debt securities) totaling approximately $3.795 billion across multiple bond and note issuances with trade dates of 5/27–5/28/2026. While Item 2.03 is technically designed for "creation of a direct financial obligation," the filing itself explicitly states that "although Consolidated Obligations issuance is material to the FHLB, we have not made a judgment as to the materiality of any particular Consolidated Obligation or Obligations." The registrant's own caveat and the routine nature of debt issuance for a Federal Home Loan Bank (whose primary business is funding through capital markets) suggest this is a material but routine disclosure that does not fit cleanly into the more specific event categories (e.g., not a covenant breach, not a going-concern issue, not a restatement). The scale of issuance ($3.795B) is material to investors, but the disclosure is administrative in character.
View raw filing on EDGAR →The filing discloses quarterly financial results for Q3 ended April 30, 2026 via a press release furnished as Exhibit 99.1. Item 2.02 is the standard vehicle for earnings releases, and the disclosure explicitly references announcement of "financial results" for the quarter. This is a material event affecting investor assessment of the company's operational and financial performance.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligation bonds totaling $120 million across four tranches (maturing 2029–2037 with coupons of 4.25%–5.25%), which are material funding activities for a Federal Home Loan Bank. While the filing explicitly states "consolidated obligations issuance is material to the Bank," the event does not fit cleanly into the standard taxonomy: it is neither a traditional debt covenant breach (Item 2.04) nor a discrete M&A or capital-raising event (dilutive_issuance applies to equity, not debt). The disclosure is routine for a wholesale funding institution but material to investors assessing the Bank's capital structure and funding costs.
View raw filing on EDGAR →This Item 2.03 disclosure reports the issuance of consolidated obligations (bonds and discount notes) totaling approximately $2.5 billion across multiple tranches with varying maturities and rate structures. While Item 2.03 typically signals covenant breaches or direct financial obligations under distress, this filing discloses routine debt issuances by a Federal Home Loan Bank in the ordinary course of funding operations. The disclosure is material to investors as it reflects significant new debt obligations, but the event itself—scheduled debt issuance—does not fit cleanly into the more specific event categories (covenant_breach implies financial stress; ma_activity implies acquisition/disposition). The Bank explicitly notes that "although certain aggregated issuances of consolidated obligations are material to the Bank, we have not made a judgment as to the materiality of any particular consolidated obligation," suggesting this is standard periodic reporting of debt activity rather than a triggering financial event.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligations (bonds and discount notes) totaling approximately $4.785 billion across nine separate securities issued in late May and early June 2026. While Item 2.03 is technically the appropriate disclosure vehicle for debt issuances, the taxonomy does not include a specific "debt_issuance" category. The event is material to the registrant's financial position and capital structure, but does not fit cleanly into the more specific event types (covenant_breach, going_concern, etc.). This is a routine capital markets activity for a Federal Home Loan Bank, disclosed in compliance with Item 2.03 requirements.
View raw filing on EDGAR →This Item 2.03 disclosure reports the Federal Home Loan Bank of Indianapolis becoming the primary obligor on consolidated obligation bonds totaling approximately $360 million in par value across three separate issuances with maturities of one to two years. While Item 2.03 is technically designated for "Creation of a Direct Financial Obligation," the disclosure does not fit cleanly into the covenant_breach category (no breach alleged) and the bonds appear to be routine consolidated obligations of the FHLBank system rather than a triggering event of financial distress. The materiality lies in the assumption of substantial debt obligations, but the event is better classified as a general material financial obligation rather than a specific covenant violation or other more acute event type.
View raw filing on EDGAR →This 8-K Item 2.03 discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds totaling approximately $172.45 million across six bond offerings with trade dates of 5/27/2026. While Item 2.03 typically signals covenant_breach or debt-related stress events, this filing is a routine disclosure of debt issuance in the ordinary course of business by a Federal Home Loan Bank, which regularly accesses capital markets. The Bank explicitly notes it "has not made a judgment as to the materiality of these consolidated obligation bonds," and the disclosure is primarily informational rather than indicative of financial distress or a triggering covenant event. This is material to investors as a significant debt issuance, but does not fit the more specific event categories (covenant_breach implies default/acceleration; ma_activity implies acquisition/disposition).
View raw filing on EDGAR →Partners Group Lending Fund disclosed an unregistered sale of Class M and Class I units totaling 39,871 units to accredited investors under Section 4(a)(2) and Regulation D exemptions.
View raw filing on EDGAR →The Fund reported its Net Asset Value (NAV) per Unit as of April 30, 2026 ($1.5013 for both Class I and M Units), aggregate NAV of approximately $317.2 million, and detailed portfolio statistics including 59 portfolio companies, asset allocations, and industry concentrations.
View raw filing on EDGAR →LendingClub Corp voluntarily withdrew its listing from the NYSE and transferred its listing to Nasdaq, effective June 18–22, 2026, concurrent with a rebranding to Happen, Inc. and a ticker change to 'HAPN'. This material transfer of listing venue affects investor trading access and the company's market profile.
View raw filing on EDGAR →The Audit Committee concluded on May 29, 2026 that the Company's previously issued consolidated financial statements for the three and nine months ended March 31, 2026 should no longer be relied upon due to a formula omission error in the weighted-average shares calculation that overstated basic and diluted EPS by $0.02 and $0.01 respectively. The Company intends to file a Form 10-Q/A to restate the affected financial statements, and management identified a material weakness in internal control over financial reporting related to the error. This is a classic financial restatement disclosure under Item 4.02.
View raw filing on EDGAR →The filing discloses the appointment of Georgina Smith as Chief Accounting Officer effective June 1, 2026, with detailed background information on her qualifications and prior roles. While the section also mentions Bernard Skaggs's termination as CFO, the substantive disclosure centers on the appointment of a new accounting officer to a material position. The appointment of a CAO is material to investors assessing the company's financial reporting and internal control infrastructure.
View raw filing on EDGAR →UroGen disclosed settlement and termination of patent litigation with Teva regarding Jelmyto, resolving a dispute over a generic ANDA submission. The settlement grants Teva a non-exclusive license to sell generic Jelmyto beginning September 15, 2030, and terminates all ongoing patent litigation in the U.S. District Court for the District of Delaware. This material litigation settlement directly affects the Company's competitive position and revenue protection for a key product.
View raw filing on EDGAR →Jeffrey Brown was appointed to multiple senior officer positions on June 1, 2026, including Vice-President and Principal Financial Officer of the parent company and President and Chief Operating Officer of key subsidiaries. While the disclosure includes compensatory details (base salary of $275,000, 100,000 share grant, severance terms), the principal disclosed action is the appointment itself to these material executive roles. The appointment is material to investors as it affects the registrant's senior management structure and financial oversight.
View raw filing on EDGAR →This Item 5.07 disclosure reports the results of HighPeak Energy's 2026 Annual Meeting of Stockholders held on June 2, 2026, including voting outcomes on four proposals: election of three Class C directors (Jason A. Edgeworth, Larry C. Oldham, and Daniel Silver), approval of named executive officer compensation (say-on-pay), approval of one-year frequency for future say-on-pay votes, and ratification of Weaver and Tidwell, L.L.P. as independent auditor. The detailed vote tallies for each proposal are provided, making this a clear shareholder_vote_results disclosure that is material to investors assessing board composition and governance.
View raw filing on EDGAR →This disclosure describes the Fiscal 2026 Executive Incentive Plan approved by the Compensation Committee and Board on June 1, 2026, establishing target cash incentive amounts and performance metrics (non-GAAP net income, revenues, and operating expenses) for the CEO and CFO. This is a compensatory arrangement disclosure under Item 5.02(e), distinct from executive departures or appointments.
View raw filing on EDGAR →Granite Construction closed a $600 million senior notes offering on June 2, 2026, entering into a material definitive Indenture agreement. The company intends to use proceeds to redeem convertible notes and repay credit facility borrowings, representing a material capital structure and financing event.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from NexPoint Real Estate Finance's June 2, 2026 Annual Meeting of Stockholders. The filing reports voting outcomes on five matters: director elections, advisory compensation votes, auditor ratification, and approval of common stock issuance upon Series C Preferred Stock redemption. All matters were approved by stockholders, with detailed vote tallies provided for each proposal.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from NexPoint Residential Trust's Annual Meeting held on June 2, 2026. The filing reports voting outcomes on four matters: election of seven directors, advisory approval of named executive officer compensation, frequency of future advisory votes on compensation, and ratification of KPMG LLP as independent auditor. All matters were approved by stockholders, with detailed vote tallies provided for each item.
View raw filing on EDGAR →NexPoint Diversified Real Estate Trust held its Annual Meeting on June 2, 2026, and shareholders voted on six matters: election of trustees, advisory approval of executive compensation, approval of the 2026 Long Term Incentive Plan, approval of common share issuance upon preferred share conversion/redemption, ratification of KPMG LLP as auditor, and a shareholder proposal regarding asset liquidation. Detailed vote tallies for each proposal are disclosed.
View raw filing on EDGAR →The Company entered into a definitive Purchase and Sale Agreement to sell real property in Kapalua, Maui for $10,000,000 plus additional acreage at $1,138,565 per acre. This is a material disposition of assets disclosed under Item 1.01, representing a significant real estate transaction that would affect investor assessment of the registrant's asset base and capital structure.
View raw filing on EDGAR →NRx Pharmaceuticals announced an underwritten public offering of common stock on June 2, 2026. While the disclosure is preliminary (announcing intent rather than completion), a registered public offering of equity is a material dilutive issuance that would affect shareholder ownership and is disclosed under Item 8.01 (Other Events). The announcement of intent to conduct such an offering is material to investors assessing capital structure and dilution risk.
View raw filing on EDGAR →Workiva held its Annual Meeting of Stockholders on May 28, 2026, with shareholders voting on three proposals: election of three Class III directors (Crow, Herren, and Iskow), advisory approval of named executive officer compensation, and approval of an amendment to the 2014 Equity Incentive Plan increasing available shares from 17.76 million to 21.66 million.
View raw filing on EDGAR →Ron E. Jackson retired from the Board of Trustees of Pebblebrook Hotel Trust, effective May 29, 2026 at the Annual Meeting, reducing the board size from eight to seven trustees.
View raw filing on EDGAR →Shareholders voted at the May 29, 2026 Annual Meeting on four proposals: election of trustees, ratification of KPMG LLP as independent auditors, advisory approval of named executive officer compensation, and approval of a Declaration amendment.
View raw filing on EDGAR →Shareholders approved an amendment to the Declaration (charter) that materially expands shareholder rights by permitting removal of trustees without cause, not just for cause, thereby enhancing trustee accountability.
View raw filing on EDGAR →KIDZ AI disclosed a strategic pivot in its digital asset treasury strategy, shifting from Solana-focused exposure to Hyperliquid ecosystem and yield-bearing stablecoin strategies. This represents a material change in the company's investment and treasury management approach that would affect investor assessment of capital allocation and strategic direction, though it does not fit neatly into the standard 8-K event taxonomy (not M&A, impairment, earnings, or executive change).
View raw filing on EDGAR →The filing discloses entry into a material definitive agreement—the Second Amendment to a Purchase and Sale Agreement for acquisition of real property and related assets in Texas valued at $11.2 million. Although this is an amendment extending the closing date rather than initial entry, it materially modifies the transaction timeline and introduces contingencies (tax litigation resolution by June 12, 2026) that could terminate the deal. The transaction amount and conditional nature make this a material M&A activity requiring disclosure under Item 1.01.
View raw filing on EDGAR →The filing discloses a presentation used on June 1, 2026 regarding the Harmonic™ Phase 2 clinical trial for LP-300, filed under Item 7.01 (Regulation FD Disclosure). While clinical trial updates can be material to pharmaceutical investors, the 8-K provides no substantive detail about trial results, efficacy, safety, or outcomes—only that a presentation was used in discussions. Without disclosure of actual clinical data or trial milestones, this appears to be a routine disclosure of investor communications rather than a specific material event (e.g., trial completion, positive/negative results, or regulatory action).
View raw filing on EDGAR →